Lantern Pharma Inc. Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount
Lantern Pharma Inc. (LTRN) reported Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount of $961.54 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-10.
Discontinued › Notes
us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount · last filed 2022-03-10
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for the quarter ending 2021-12-31 was $245.93K, a 76.00% decline year-over-year.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for the quarter ending 2021-09-30 was $224.41K, a 415.73% increase year-over-year.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for the quarter ending 2021-06-30 was $245.68K, a 133.18% increase year-over-year.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for the quarter ending 2021-03-31 was $245.52K, a 1230.01% increase year-over-year.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for fiscal 2021 was $961.54K, a 19.35% decline from fiscal 2020.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for fiscal 2020 was $1.19M, a 912.43% increase from fiscal 2019.
- Lantern Pharma Inc. stock option, down round feature, (increase) decrease in equity, amount for fiscal 2019 was $117.76K.
| Period end | Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount 3 month | Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount 6 month | Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount 9 month | Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount 12 month |
|---|---|---|---|---|
| 2021-12-31 | $245.93K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $470.34K derived: sum of 2 quarters · filed 2022-03-10 | $716.03K derived: sum of 3 quarters · filed 2022-03-10 | $961.54K 10-K · filed 2022-03-10 |
| 2021-09-30 | $224.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $470.10K derived: sum of 2 quarters · filed 2021-11-01 | $715.62K 10-Q · filed 2021-11-01 | $1.74M derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | $245.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $491.20K 10-Q · filed 2021-07-29 | $1.52M derived: sum of 3 quarters · filed 2022-03-10 | $1.56M derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | $245.52K 10-Q · filed 2021-05-03 | $1.27M derived: sum of 2 quarters · filed 2022-03-10 | $1.31M derived: sum of 3 quarters · filed 2022-03-10 | $1.42M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.07M derived: sum of 2 quarters · filed 2022-03-10 | $1.17M derived: sum of 3 quarters · filed 2022-03-10 | $1.19M 10-K · filed 2022-03-10 |
| 2020-09-30 | $43.51K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $148.88K derived: sum of 2 quarters · filed 2021-11-01 | $167.34K 10-Q · filed 2021-11-01 | $230.74K derived: sum of 4 quarters · filed 2021-11-01 |
| 2020-06-30 | $105.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $123.82K 10-Q · filed 2021-07-29 | $187.23K derived: sum of 3 quarters · filed 2021-07-29 | $220.02K derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $18.46K 10-Q · filed 2021-05-03 | $81.86K derived: sum of 2 quarters · filed 2021-05-03 | $114.66K derived: sum of 3 quarters · filed 2021-05-03 | |
| 2019-12-31 | $63.40K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $96.20K derived: sum of 2 quarters · filed 2021-03-10 | $117.76K 10-K · filed 2021-03-10 | |
| 2019-09-30 | $32.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $54.36K 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $21.56K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |